Trading update and notice of results

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

Trading update for six months ended 31 July 2025

Notice of interim results

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company pioneering best-in-class, specialist neonatal intensive care medical devices, provides a trading update for six months ended 31 July 2025.

Highlights

· Revenue growth of 41% to £24.0 million (H1 FY25: £17.0 million)

· Improved gross margins due to favourable product mix including strong sales of capital items

· $6 million humanitarian aid contract fully delivered in the period

· Strong sales momentum in H1 FY26 expected to continue into H2 FY26

· Net debt reduced by £1.6 million to £6.7 million (31 January 2025: £8.3 million), strengthening the balance sheet

Revenues for the period were £24.0 million (H1 FY25: £17.0 million) which is a 41% increase on the same period last year, ahead of market expectations, and represents record half year revenues for the Group reflecting the benefits of the back-to-basics approach implemented last year. Gross margins also recovered benefitting from an improved sales mix of higher margin neonatal products, with strong sales of capital items, leading to improved profitability when combined with the impact of cost savings implemented last year.

The Group's contract with the global humanitarian aid group focusing on child and infant welfare, the largest single contract the Company has won to date, at $6 million for SLE6000 and SLE1500 ventilators plus associated accessories and consumables was fully delivered in the period and a majority of payment received. The remainder of this payment, relating to installation of the equipment, is expected to be received in early H2.

The Middle Eastern contract is also progressing, with the first shipment of ventilators and accessories delivered in the period and payment received. The remainder of this is contract is expected to be delivered in H2 pending receipt of a letter of credit.

At 31 July 2025, the Group's net debt (excluding IFRS16 lease liabilities) was £6.7 million, a reduction of £1.6 million from £8.3 million at 31 January 2025 due to the strong trading performance in the period combined with an improving working capital position, with a further improvement in net debt expected to be realised in the second half.

Raffi Stepanian, CEO of Inspiration Healthcare plc commented: "I am pleased to report that we have had a robust first half performance and continue to see the benefits of our turnaround strategy. With strong revenue growth of 41%, enhanced gross margins, a significant improvement in EBITDA and a reduction in net debt, we are seeing clear evidence that our disciplined 'back-to-basics' approach is driving financial recovery and setting a solid foundation for continued momentum into the second half of the year and beyond.

"Our pipeline is strong and we are continuing an upward trajectory. We remain confident in delivering our full-year expectations and creating long-term value for shareholders."

Notice of interim results

The Group will be announcing its interim results for the six months ended 31 July 2025 on Tuesday, 7 October 2025. Analyst and investor meetings will take place to accompany the results, details of which will be announced in due course.

For further information, please contact:

About Inspiration Healthcare

Inspiration Healthcare (AIM: IHC) designs, manufactures and markets pioneering medical technology. Based in the UK, the Company specialises in neonatal intensive care medical devices, which are addressing a critical need to help to save the lives and improve the outcomes of patients, starting with the very first breaths of life.

The Company has a broad portfolio of its own products and complementary distributed products, for use in neonatal intensive care designed to support even the most premature babies throughout their hospital stay. Its own branded products range from highly sophisticated capital equipment such as ventilators for life support through to single-use disposables.

The Company sells its products directly to hospitals and healthcare providers in the UK and Ireland, where it also distributes a range of advanced medical technologies for infusion therapy. In the rest of the world the Company has an established network of distribution partners around the world giving access to more than 75 countries.

The Company operates in the UK from its world-class Manufacturing and Technology Centre in Croydon, South London and in the USA from its facility in Melbourne, Florida.

Further information on Inspiration Healthcare can be found at www.inspirationhealthcaregroup.com